Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6961 to 6975 of 8314 results

  1. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

    Technology appraisal guidance
    Discontinued

  2. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  3. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued Reference number: GID-TA10750

    Technology appraisal guidance
    Discontinued

  4. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development Reference number: GID-TA10758 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued Reference number: GID-TA10763

    Technology appraisal guidance
    Discontinued

  6. Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

    Discontinued Reference number: GID-TA10767

    Technology appraisal guidance
    Discontinued

  7. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued Reference number: GID-TA10922

    Technology appraisal guidance
    Discontinued

  9. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued Reference number: GID-TA10927

    Technology appraisal guidance
    Discontinued

  10. Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]

    Discontinued Reference number: GID-TA10934

    Technology appraisal guidance
    Discontinued

  11. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development Reference number: GID-TA10935 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued Reference number: GID-TA10963

    Technology appraisal guidance
    Discontinued

  13. Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma

    Discontinued Reference number: GID-TA10970

    Technology appraisal guidance
    Discontinued

  14. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development Reference number: GID-TA11010 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

    Technology appraisal guidance
    In development